Skip to main content

Advertisement

SpringerLink
Log in

Apolipoprotein A-I: A Molecule of Diverse Function

  • Review Article
  • Published:
Indian Journal of Clinical Biochemistry Aims and scope Submit manuscript

Abstract

Apolipoprotein A-I (apo A-I) an indispensable component and a major structural protein of high-density lipoprotein (HDL), plays a vital role in reverse cholesterol transport and cellular cholesterol homeostasis since its identification. Its multifunctional role in immunity, inflammation, apoptosis, viral, bacterial infection etc. has crossed its boundary of its potential of protecting cardiovascular system and lowering cardiovascular disease risk, attributing HDL to be known as a protective fat removal particle. Its structural homology with prostacyclin stabilization factor has contributed to its anti-clotting and anti-aggregatory effect on platelet which has potentiated its cardio-protective role as well as its therapeutic efficacy against Alzheimer’s disease. The binding affinity and neutralising action against endotoxin lipopolysaccharide, reduces the toxic manifestations of septic shock. As a negative acute phase protein, it blocks T-cell signalling of macrophages. However the recently identified anti-tumor activity of apo A-I has been highlighted in various models of melanoma, lung cancer, ovarian cancer, lymphoblastic leukaemia, gastric as well as pancreatic cancers. These cancer fighting effects are directed towards regression of tumor size and distant metastasis by its immuno modulatory activity as well as its clearing effect on serum lysophospholipids. This lowering effect on lysophospholipid concentration is utilized by apo A-I mimetic peptides to be used in retarding tumor cell proliferation and as a potential cancer therapeutic agent. Not only that, it inhibits the tumor associated neo-angiogenesis as well as brings down the matrix degrading enzymes associated with tumor metastasis. However this efficient therapeutic potential of apo A-I as an anti tumor agent awaits further future experimental studies in humans.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Wasan KM, Brocks DR, Lee SD, Sachs-Barrable K, Thornton SJ. Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery. Nat Rev Drug Discov. 2008;7(1):84–99.

    Article  CAS  PubMed  Google Scholar 

  2. Phillips JC, Wrigglers W, Li Z, Schulten K. Predicting the structure of apolipoprotein AI in reconstituted high density lipoprotein disks. Biophys J. 1997;73:2337–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Yui Y, Aoyama T, Morishita H, Takahashi M, Takatsu Y, Kawai C. Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (apo A-I). A novel function of apo A-I. J Clin Invest. 1988;82(3):803–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Oda MN, Budamagunta MS, Borja MS, Petrlova J, Voss JC, Lagerstedt JO. The secondary structure of Apolipoprotein A-1 on 9.6 nm reconstituted high density lipoprotein determined by EPR Spectroscopy. FEBS J. 2013;280(14):3416–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Cuellar LÁ, Prieto ED, Cabaleiro LV, Garda HA. Apolipoprotein A-I configuration and cell cholesterol efflux activity of discoidal lipoproteins depend on the reconstitution process. Biochim Biophys Acta. 2014;1841(1):180–9.

    Article  CAS  PubMed  Google Scholar 

  6. Frank PG, Marcel YL. Apolipoprotein A-I: structure-function relationships. J Lipid Res. 2000;41(6):853–72.

    CAS  PubMed  Google Scholar 

  7. Adachi E, Kosaka A, Tsuji K, Mizuguchi C, Kawashima H, Shigenaga A, et al. The extreme N-terminal region of human apolipoprotein A-I has a strong propensity to form amyloid fibrils. FEBS Lett. 2014;588(3):389–94.

    Article  CAS  PubMed  Google Scholar 

  8. Arinami T, Hirano T, Kobayashi K, Yamanouchi Y, Hamaguchi H. Assignment of the apolipoprotein A-I gene to 11q23 based on RFLP in a case with a partial deletion of chromosome 11, del(11)(q23.3→qter). Hum Genet. 1990;85(1):39–40.

    Article  CAS  PubMed  Google Scholar 

  9. Tall AR, Wang N. Tangier disease as a test of reverse cholesterol transport hypothesis. J Clin Invest. 2000;106(10):1205–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Franceschini G, Sirtori M, Gianfranceschi G, Sirtori CR. Relation between the HDL apoproteins and A-I isoproteins in subjects with the AIMilano abnormality. Metab Clin Exp. 1981;30(5):502–9.

    Article  CAS  PubMed  Google Scholar 

  11. Dastani Z, Dangoisse C, Boucher B, Desbiens K, Krimbou L, Dufour R, et al. A novel nonsense apolipoprotein A-I mutation (apoA-I(E136X)) causes low HDL cholesterol in French Canadians. Atherosclerosis. 2006;185(1):127–36.

    Article  CAS  PubMed  Google Scholar 

  12. Huang Y, DiDonato JA, Levison BS, Schmitt D, Li L, Wu Y, et al. An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat Med. 2014;20(2):193–203.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Mossuz P, Bouamrani A, Brugière S, Arlotto M, Hermouet S, Lippert E, et al. Apolipoprotein A1: a new serum marker correlated to JAK2 V617F proportion at diagnosis in patients with polycythemia vera. Proteomics Clin Appl. 2007;1(12):1605–12.

    Article  CAS  PubMed  Google Scholar 

  14. Koldamova RP, Lefterov IM, Lefterova MI, Lazo JS. Apolipoprotein AI directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity. Biochemistry. 2001;40(12):3553–60.

    Article  CAS  PubMed  Google Scholar 

  15. Zamanian-Daryoush M, Lindner D, Tallant TC, Wang Z, Buffa J, Klipfell E, et al. The cardioprotective protein apolipoprotein A I promotes potent anti-tumorigenic effects. J Biol Chem. 2013;288(29):21237–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Rye KA, Bursill CA, Lambert G, Tabet F, Barter PJ. The metabolism and anti-atherogenic properties of HDL. J Lipid Res. 2009;50(Suppl):S195–200.

    PubMed  PubMed Central  Google Scholar 

  17. Camont L, Chapman MJ, Kontush A. Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med. 2011;17:594–603.

    Article  CAS  PubMed  Google Scholar 

  18. Gordon SM, Hofmann S, Askew DS, Davidson WS. High density lipoprotein:it’s not just about lipid transport anymore. Trends Endocrinol Metab. 2011;22:9–15.

    Article  CAS  PubMed  Google Scholar 

  19. Vanhamme L, Paturiaux-Hanocq F, Poelvoorde P, Nolan DP, Lins L, Van Den Abbeele J, et al. Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature. 2003;422:83–7.

    Article  CAS  PubMed  Google Scholar 

  20. Levine DM, Parker TS, Donnelly TM, Walsh A, Rubin AL. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci USA. 1993;90:12040–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Grunfeld C, Marshall M, Shisenega JK, Moser AH, Tobias P, Feingold KR. Lipoproteins inhibit macrophage activation by lipoteichoic acid. J Lipid Res. 1999;40:245–54.

    CAS  PubMed  Google Scholar 

  22. Ma J, Liao XL, Lou B, Wu MP. Role of apolipoprotein A-I in protecting against endotoxin toxicity. ActaBiochim Biophys Sin (Shanghai). 2004;36(6):419–24.

    Article  CAS  Google Scholar 

  23. Gordon SM, Hofmann S, Askew DS, Davidson WS. High density lipoprotein: it’s not just about lipid transport anymore. Trends Endocrinol Metab. 2011;22(1):9–15.

    Article  CAS  PubMed  Google Scholar 

  24. Singh IP, Chopra AK, Coppenhaver DH, Ananatharamaiah GM, Baron S. Lipoproteins account for part of the broad non-specific antiviral activity of human serum. Antiviral Res. 1999;42(3):211–8.

    Article  CAS  PubMed  Google Scholar 

  25. Srinivas RV, Birkedal B, Owens RJ, Ananatharamaiah GM, Segrest JP, Compans RW. Antiviral effects of Apolipoprotein AI and its synthetic amphipathic peptide analogs. Virology. 1990;176(1):48.

    Article  CAS  PubMed  Google Scholar 

  26. Wilhelm AJ, Zabalawi M, Owen JS, Shah D, Grayson JM, Major AS, et al. Apo lipoprotein A1 Modulates regulatory T cells in auto immune LDL r-/-, Apo A 1-/- mice. J Biol Chem. 2010;285(46):16158.

    Article  Google Scholar 

  27. Catapano AL, Pirillo A, Bonacina F, Norata GD. HDL in innate and adaptive immunity. Cardiovasc Res. 2014;103(3):372–83. doi:10.1093/cvr/cvu150.

    Article  CAS  PubMed  Google Scholar 

  28. Hyka N, Dayer JM, Modoux C, Kohno T, Edwards CK III, Roux-Lombard P, et al. Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood. 2001;97:2381–9.

    Article  CAS  PubMed  Google Scholar 

  29. Feldmann M, Taylor P, Paleolog E, Brennan FM, Maini RN. Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn’s disease: analysis of the mechanism of action predicts utility in other diseases. Transpl Proc. 1998;30:4126–7.

    Article  Google Scholar 

  30. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, ATTRACT Study Group, et al. Infliximab(chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet. 1999;354(9194):1932–9.

    Article  CAS  PubMed  Google Scholar 

  31. Kalden JR, Breedveld FC, Burkhardt H, Burmester GR. Immunological treatment of autoimmune diseases. Adv Immunol. 1998;68:333–418.

    Article  CAS  PubMed  Google Scholar 

  32. Tangirala RK, Tsukamoto K, Chun SH, Usher D, Pure E, Rader DJ. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoproteinA-I in mice. Circulation. 1999;100:1816–22.

    Article  CAS  PubMed  Google Scholar 

  33. Paszty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest. 1994;94:899–903.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Vergnes L, Baroukh N, Ostos MA, Castro G, Duverger N, Nanjee MN, et al. Expression of human apolipoprotein A-I/C-III/A-IV gene cluster in mice induces hyperlipidemia but reduces atherogenesis. Arterioscler Thromb Vasc Biol. 2000;20:2266–74.

    Article  Google Scholar 

  35. Neale, T.: HDL component an enemy to cancer in mice. http://www.medpagetoday.com/Cardiology/Dyslipidemia/40579 (2013). Accessed 22 July 2013.

  36. Ehmann M, Felix K, Hartmann D, Schnölzer M, Nees M, Vorderwülbecke S, et al. Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas. 2007;34:205–14.

    Article  CAS  PubMed  Google Scholar 

  37. Chong P-K, Lee H, Zhou J, Liu S-C, Loh MCS, So JBY, et al. Reduced plasma APOA1 level is associated with Gastric Tumor Growth in MKN45 mouse xenograft mode. J Proteomics. 2010;73(8):1632–40.

    Article  CAS  PubMed  Google Scholar 

  38. Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, Farias-Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics. 2005;5:4589–96.

    Article  CAS  PubMed  Google Scholar 

  39. Halton JM, Nazir DJ, McQueen MJ, Barr RD. Blood lipid profiles in children with acute lymphoblastic leukemia. Cancer. 1998;83:379–84.

    Article  CAS  PubMed  Google Scholar 

  40. Scribano D, Baroni S, Pagano L, Zuppi C, Lione G, Giardina B, et al. Return to normal values of lipid pattern after effective chemotherapy in acute lymphoblastic leukemia. Haematologica. 1996;81:343–5.

    CAS  PubMed  Google Scholar 

  41. Li H, Wang D, Zhang H, Kirmani K, Zhao Z, Steinmetz R, et al. Lysophosphatidic acid stimulates cell migration, invasion, and colony formation as well as tumorigenesis/metastasis of mouse ovarian cancer in immunocompetent mice. Mol Cancer Ther. 2009;8:1692–701.

    Article  CAS  PubMed  Google Scholar 

  42. Su F, Kozak KR, Imaizumi S, Gao F, Amneus MW, Grijalva V, et al. Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci USA. 2010;107:19997–20002.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Neyen C, Pluddemann A, Mukhopadhyay S, Maniati E, Bossard M, Gordon S, et al. Macrophage scavenger receptor a promotes tumor progression in murine models of ovarian and pancreatic cancer. J Immunol. 2013;190:000–000.

  44. Neyen C, Mukhopadhyay S, Gordon S, Hagemann T. An apolipoprotein A-I mimetic targets scavenger receptor A on tumor-associated macrophages A prospective anticancer treatment. Oncoimmunology. 2013;2(6):e24461. doi:10.4161/onci.24461.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Hofmann UB, Houben R, Bröcker EB, Becker JC. Role of matrix metalloproteinases in melanoma cell invasion. Biochimie. 2005;87:307–14.

    Article  CAS  PubMed  Google Scholar 

  46. Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 2011;32:19–25.

    Article  CAS  PubMed  Google Scholar 

  47. Piras F, Murtas D, Minerba L, Ugalde J, Floris C, Maxia C, et al. Nuclear survivin is associated with disease recurrence and poor survival in patients with cutaneous malignant melanoma. Histopathology. 2007;50:835–42.

    Article  CAS  PubMed  Google Scholar 

  48. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ, et al. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol. 1995;15:1987–94.

    Article  CAS  PubMed  Google Scholar 

  49. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292–300.

    Article  CAS  PubMed  Google Scholar 

  50. Tardif JC, Gregoire J, L’Allier PL, Ibrahim R, Lesperance J, Heinonen TM, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA. 2007;297:1675–82.

    Article  PubMed  Google Scholar 

  51. Sacks FM, Rudel LL, Conner A, Akeefe H, Kostner G, Baki T, et al. Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo. J Lipid Res. 2009;50:894–907.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biochemistry, AIIMS, Bhubaneswar, Odisha, India

    Manaswini Mangaraj

  2. Department of Biochemistry, AIIMS, Raipur, Chhattisgarh, 492099, India

    Rachita Nanda

  3. Department of Biochemistry, SCB Medical College, Cuttack, Odisha, India

    Suchismita Panda

Authors
  1. Manaswini Mangaraj
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rachita Nanda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Suchismita Panda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rachita Nanda.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mangaraj, M., Nanda, R. & Panda, S. Apolipoprotein A-I: A Molecule of Diverse Function. Ind J Clin Biochem 31, 253–259 (2016). https://doi.org/10.1007/s12291-015-0513-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12291-015-0513-1

Keywords

Search

Navigation